ArticleCureus2026
Marked Clinical and Functional Response to Tezepelumab After Failure of Anti-Interleukin-5 (Anti-IL-5) Therapy in Severe Asthma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biologics targeting type 2 inflammation, including anti-interleukin-5 (anti-IL-5) antibodies, have improved outcomes in severe asthma, but some patients remain symptomatic with apparently persistent severe airflow limitation. We report an 86-year-old woman with long-standing severe asthma who initially had high blood eosinophil counts and serum immunoglobulin E (IgE) levels. She responded to mepolizumab for years, while airflow limitation persisted. She developed an exacerbation seven years after mepolizumab initiation despite ongoing mepolizumab and inhaled triple therapy, while type 2 biomarkers normalized. She continued to experience dyspnea with triggers such as cold air and pollen. After switching from mepolizumab to tezepelumab, her symptoms rapidly resolved; forced expiratory volume in one second (FEV₁) increased from 0.64 L (45.7% predicted) to 1.45 L (103% predicted) within two months, and the concave flow-volume loop became almost normal. This case suggests that chronic airflow limitation in severe asthma is not always irreversible and that switching to tezepelumab may induce dramatic functional recovery even after anti-IL-5 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.